{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["35(3)"],"submitter":["Kuendgen A"],"pubmed_abstract":["In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As"],"journal":["Leukemia"],"pagination":["835-849"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7932916"],"repository":["biostudies-literature"],"pubmed_title":["Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS."],"pmcid":["PMC7932916"],"pubmed_authors":["Tuechler H","Pfeilstocker M","Sill H","Hildebrandt B","Xicoy B","Pedro C","Baldus CD","Haase D","Kuendgen A","Costa D","Esteve J","Garcia-Manero G","Valent P","Lubbert M","DeZern AE","Haas R","Cobo F","Cazzola M","Oiartzabal I","Diez-Campelo M","Sole F","Komrokji RS","Ganster C","Germing U","Calvo X","Roboz GJ","Schroeder T","Giagounidis A","Sanz G","Nomdedeu B","Lopez-Pavia M","Nomdedeu M","Cedena MT","Van de Loosdrecht AA","Machherndl-Spandl S","Schlenk RF","Dohner H","Stauder R","Platzbecker U","Pereira A","Merchan B","Greenberg PL","Della Porta MG","Steensma DP","Sekeres MA","List A","Grau J","Martinez-de-Sola M","Voso MT","Blum S"],"additional_accession":[]},"is_claimable":false,"name":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.","description":"In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-20T02:30:01.018Z","creation":"2025-04-20T02:30:01.018Z"},"accession":"S-EPMC7932916","cross_references":{"pubmed":["32595214"],"doi":["10.1038/s41375-020-0917-7"]}}